@article{70a91de943924afdaf9eaa43bedd6c4d,
title = "Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study",
abstract = "Introduction: Pain, functional impairment, anxiety, and depression associated with joint disease may affect health-related quality of life (HRQoL) in people with hemophilia. Objective: To report detailed patient-reported outcomes (PRO) assessments related to HRQoL in participants in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. Methods: Pain and HRQoL were assessed via PRO instruments in US adult males with hemophilia A or B and a history of joint pain or bleeding. PRO instruments included EQ-5D-5L with visual analog scale, Brief Pain Inventory v2 Short Form, SF-36v2, and Hemophilia Activities List. Instrument domain and item responses were described. Results: Responses were collected from 381 adult males with a median age of 34 years. Pain was observed across instruments and affected daily activities and quality of life. Respondents reported functional impairment that limited the kind of work and activities they participated in, with activities involving the lower extremities being most affected. A high prevalence of mental health disorders was identified across instruments. Conclusions: Pain and HRQoL were evaluated using multiple PRO instruments, which vary in timescales of assessment and levels of detail. More consistent clinical assessments and patient dialog regarding pain and aspects of HRQoL may help drive improved outcomes.",
keywords = "coagulation disorders, quality of life",
author = "Buckner, {Tyler W.} and Katharine Batt and Doris Quon and Michelle Witkop and Michael Recht and Craig Kessler and Kimberly Baumann and Grace Hernandez and Michael Wang and Cooper, {David L.} and Kempton, {Christine L.}",
note = "Funding Information: T. Buckner has served on advisory boards with CSL Behring, Genentech, Novo Nordisk, Pfizer, and Shire and as a consultant for Uniqure. K. Batt has received grant/research support from Novo Nordisk Inc. and is a scientific advisor for Precision Health Economics. D. Quon is on advisory boards for Bayer, Bioverativ, Genentech, and Novo Nordisk and speakers bureaus for Bioverativ, Grifols, Novo Nordisk, Pfizer, and Shire. M. Witkop is currently Head of Research at the National Hemophilia Foundation. At the time of this research MW had received grant funding from Pfizer; served on advisory boards with Aptevo, Baxter Bioscience, Biogen Idec, Novo Nordisk, Octapharma, and Pfizer; and was on the Novo Nordisk Speakers Bureau. M. Recht has received grant/research support from Baxter, Biogen Idec, Novo Nordisk, and Pfizer and served as a consultant to Kedrion and Novo Nordisk. C. Kessler has served on advisory boards for Baxalta, Bayer, Biogen, Genentech, Grifols, Novo Nordisk, Octapharma, and Pfizer and has received grant/research support from Baxter, Bayer, Novo Nordisk, and Octapharma. K. Baumann has served as a consultant for Bayer and Novo Nordisk, and as a speaker Funding Information: The P-FiQ study was managed by Quintiles Real World and Late Phase, Boston, Massachusetts, and Rockville, Maryland, with statistical analyses provided by Jennifer James, Senior Biostatistician, and was supported financially by Novo Nordisk Inc. Writing assistance was provided by Nicole Yohn, PhD, of ETHOS Health Communications in Yardley, Pennsylvania, and was supported financially by Novo Nordisk Inc., Plainsboro, New Jersey, in compliance with international Good Publication Practice guidelines. Publisher Copyright: {\textcopyright} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2018",
month = apr,
doi = "10.1111/ejh.13027",
language = "English (US)",
volume = "100",
pages = "5--13",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
}